How do Cingulate's Q3 2025 R&D expenses, which increased by 99.5% year-over-year, compare to industry averages for biopharmaceutical companies in late-stage development?

Cingulate Inc.'s Research and Development (R&D) expenses for Q3 2025 totaled $2.8 million, marking a substantial 99.5% increase year-over-year. This increase was primarily driven by higher personnel expenses, manufacturing costs, and regulatory costs, including separation costs for an executive and accrued contingent bonus plan costs related to the NDA submission of CTx-1301.1 The company is in late-stage development, with activities focused on the NDA submission for its lead asset, CTx-1301, and anticipates commercialization in mid-2026, pending FDA approval.2

Comparing Cingulate's R&D expenditure to industry averages for biopharmaceutical companies in late-stage development reveals a varied landscape:

• Cingulate's Absolute Spend: While the percentage increase is high, Cingulate's absolute R&D spend of $2.8 million for Q3 2025 is relatively modest compared to some other companies in similar development stages.
• Peer Comparisons:
• NewAmsterdam Pharma Co. N.V. (NAMS), which had completed several Phase 3 clinical trials by late 2024, reported R&D expenses of $44.8 million for Q1 2025.3
• Atossa Therapeutics, Inc. (ATOS), engaged in (Z)-endoxifen trials, recorded R&D expenses of $5.37 million for Q3 2025, a 57% increase year-over-year.4
• Industry Context: Late-stage clinical trials, such as Phase III, are generally described as "especially expensive," often requiring "tens or hundreds of millions of dollars" over several years.5 The total biopharma R&D spend globally was projected to be $293 billion in 2024, indicating the significant capital intensity of the sector.6

The 99.5% year-over-year increase for Cingulate reflects intensified activity as the company approaches regulatory submission and potential commercialization for CTx-1301. However, the lower absolute dollar amount suggests a potentially more focused or smaller-scale R&D operation compared to larger biopharmaceutical entities, or a different stage within "late-stage development" where certain major trial costs may have already been incurred or are yet to come.